AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8127283 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg for gastroscopy, 4 mg for colonoscopy)
Number of subjects: 1025
Study 6388776 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth room setting
Number of subjects: 114
Study 6388776 — intervention group
Group type: COMPARATOR
Intervention: Conventional setting
Number of subjects: 114
Study 30421119 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Liver Resection Difficulty Score (LDS)
Number of subjects: 444
Study 30369300 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 8
Study 30369300 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 8
Study 30369300 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 8
Study 26719225 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test (FIT)
Number of subjects: 16087
Study 26719225 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced CT Colonography (r‐CTC)
Number of subjects: 16087
Study 26719225 — intervention group
Group type: EXPERIMENTAL
Intervention: Full CT Colonography (f‐CTC)
Number of subjects: 16087
Study 26719225 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Colonoscopy (OC)
Number of subjects: 16087
Study 25142085 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding hydration
Number of subjects: 138
Study 25142085 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate hydration (1-h 250 mL 1.4%)
Number of subjects: 138
Study 25142085 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate hydration
Number of subjects: 138
Study 22132722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg, 0.05 mL of solution prepared from avastin, 100 mg/4 mL vial) at the end of surgery
Number of subjects: 57
Study 22132722 — intervention group
Group type: COMPARATOR
Intervention: Control group (phacoemulsification with intraocular lens implantation alone)
Number of subjects: 57
Study 22132722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 57
Study 22132722 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 20664198 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 2091
Study 20664198 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2091
Study 17684208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free milk (n = 18)
Number of subjects: 56
Study 17684208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free soy protein (n = 19)
Number of subjects: 56
Study 17684208 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (control group; n = 19)
Number of subjects: 56
Study 16522417 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA) with low-dose oxytocin
Number of subjects: 19
Study 16522417 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA) with high-dose oxytocin
Number of subjects: 19
Study 16522417 — intervention group
Group type: COMPARATOR
Intervention: Opioid analgesia
Number of subjects: 19
Study 15278044 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based simulator training (10 hours)
Number of subjects: 22
Study 15278044 — intervention group
Group type: COMPARATOR
Intervention: Non-pretrained group
Number of subjects: 22
Study 10981820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsating magnetic field (induction: 25-80 microT; frequency: 200 Hz) applied for 3 weeks (5 days/week, twice a day for 8 minutes each)
Number of subjects: 7
Study 8814695 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved radiotherapy alone or radiotherapy plus 6 months of chlorambucil in limited disease (Ann Arbor stage I and II)
Number of subjects: 398
Study 8814695 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in disseminated disease (Ann Arbor stage III)
Number of subjects: 398
Study 8814695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ann Arbor stage I disease
Number of subjects: 398
Study 8814695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ann Arbor stage II disease
Number of subjects: 398
Study 8814695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ann Arbor stage III disease
Number of subjects: 398
Study 8814695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ann Arbor stage IV disease
Number of subjects: 398
Study 1706244 — intervention group
Group type: COMPARATOR
Intervention: beta-hCG vaccine formulations
Number of subjects: 18
Study 6594926 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16-213
Number of subjects: 38
Study 30998721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernal keratoconjunctivitis prevalence
Number of subjects: 574
Study 30998721 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 574
Study 30998721 — intervention group
Group type: EXPERIMENTAL
Intervention: Close animal contact
Number of subjects: 574
Study 30998721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust exposure
Number of subjects: 574
Study 30998721 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal systemic allergy history
Number of subjects: 574
Study 28619303 — intervention group
Group type: EXPERIMENTAL
Intervention: Light pressure stroking massage with sesame oil
Number of subjects: 40
Study 28619303 — intervention group
Group type: COMPARATOR
Intervention: Liquid paraffin (placebo)
Number of subjects: 40
Study 25548091 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic horseback riding course for 10 weeks
Number of subjects: 15
Study 25548091 — intervention group
Group type: COMPARATOR
Intervention: Control group (age matched to riders)
Number of subjects: 15
Study 23245772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 42
Study 23245772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 42
Study 23245772 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 42
Study 20935058 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day of 0.25 mg palonosetron
Number of subjects: 73
Study 20935058 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of 0.25 mg palonosetron
Number of subjects: 73
Study 20935058 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of 0.25 mg palonosetron
Number of subjects: 73
Study 19840579 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of clopidogrel for 30 days (group II)
Number of subjects: 59
Study 19840579 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of clopidogrel (group III)
Number of subjects: 59
Study 19840579 — intervention group
Group type: COMPARATOR
Intervention: 75 mg of clopidogrel (group I)
Number of subjects: 59
Study 16938749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin (intended INR 1.3-1.9)
Number of subjects: 73
Study 16938749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warfarin)
Number of subjects: 73
Study 16938749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin
Number of subjects: 73
Study 16938749 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 15522049 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD) patients
Number of subjects: 40
Study 10902794 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 51
Study 10902794 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 51
Study 10902794 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study 11990165 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol administered via Rotahaler at various altitudes
Number of subjects: 19
Study 7870942 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 7870942 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0
Study 7870942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3774871 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine (600 mg daily)
Number of subjects: 81
Study 3774871 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (150 mg daily)
Number of subjects: 81
Study 3774871 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine
Number of subjects: 81
Study 3774871 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 81
Study 31881995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) specific for LLD, delivered in 15 sessions over 8 weeks (twice per week) with a 6-month follow-up period.
Number of subjects: 248
Study 31881995 — intervention group
Group type: COMPARATOR
Intervention: Supportive unspecific intervention (SUI) of the same quantity as CBT.
Number of subjects: 248
Study 31881995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) specific for LLD.
Number of subjects: 248
Study 31881995 — intervention group
Group type: COMPARATOR
Intervention: Supportive unspecific intervention (SUI).
Number of subjects: 248
Study 30387904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 335
Study 30387904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin with cognitive-enhancing medication
Number of subjects: 335
Study 30387904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin without cognitive-enhancing medication
Number of subjects: 335
Study 27447961 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal outreach (letter/email/telephone)
Number of subjects: 1100
Study 27447961 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone outreach
Number of subjects: 1100
Study 27447961 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1100
Study 27447961 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal outreach
Number of subjects: 1100
Study 27447961 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter outreach
Number of subjects: 1100
Study 24401360 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreous application 2 + etching (G5)
Number of subjects: 84
Study 24401360 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreous application 1 + etching with hydrofluoric acid (G3)
Number of subjects: 84
Study 24401360 — intervention group
Group type: COMPARATOR
Intervention: No treatment (G1)
Number of subjects: 84
Study 24401360 — intervention group
Group type: EXPERIMENTAL
Intervention: Air‐borne particle abrasion with silica‐coated aluminum oxide particles (G2)
Number of subjects: 84
Study 24401360 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreous application 1 + tribosilicatization (G4)
Number of subjects: 84
Study 24401360 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreous application 2 + tribosilicatization (G6)
Number of subjects: 84
Study 22684617 — intervention group
Group type: EXPERIMENTAL
Intervention: Polynephron dialyzer
Number of subjects: 20
Study 22684617 — intervention group
Group type: COMPARATOR
Intervention: High-flux polysulphone dialyzer
Number of subjects: 20
Study 22684617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dialyzer groups
Number of subjects: 20
Study 20153490 — intervention group
Group type: EXPERIMENTAL
Intervention: NIMGU in individuals with NGR (n = 385)
Number of subjects: 616
Study 20153490 — intervention group
Group type: EXPERIMENTAL
Intervention: NIMGU in individuals with IGR (n = 189)
Number of subjects: 616
Study 20153490 — intervention group
Group type: EXPERIMENTAL
Intervention: NIMGU in individuals with DM (n = 42)
Number of subjects: 616
Study 20153490 — intervention group
Group type: COMPARATOR
Intervention: NIMGU across groups (NGR, IGR, DM)
Number of subjects: 616
Study 20153490 — intervention group
Group type: EXPERIMENTAL
Intervention: NIMGU and percentage body fat
Number of subjects: 616
Study 20153490 — intervention group
Group type: EXPERIMENTAL
Intervention: NIMGU and 24-hour energy expenditure
Number of subjects: 616
Study 20153490 — intervention group
Group type: EXPERIMENTAL
Intervention: NIMGU and sleep energy expenditure
Number of subjects: 616
Study 18982860 — intervention group
Group type: COMPARATOR
Intervention: Chinese subjects
Number of subjects: 1236
Study 18982860 — intervention group
Group type: COMPARATOR
Intervention: Other countries subjects
Number of subjects: 1236
Study 15644072 — intervention group
Group type: EXPERIMENTAL
Intervention: Danshen
Number of subjects: 33
Study 15644072 — intervention group
Group type: COMPARATOR
Intervention: Buflomedil
Number of subjects: 33
Study 15644072 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 33
Study 11601563 — intervention group
Group type: EXPERIMENTAL
Intervention: UFA margarine
Number of subjects: 16
Study 11601563 — intervention group
Group type: COMPARATOR
Intervention: Butter
Number of subjects: 16
Study 11601563 — intervention group
Group type: COMPARATOR
Intervention: Jelly
Number of subjects: 16
Study 11601563 — intervention group
Group type: COMPARATOR
Intervention: UFA margarine + jelly
Number of subjects: 16
Study 11601563 — intervention group
Group type: COMPARATOR
Intervention: Cracker alone
Number of subjects: 16
Study 11601563 — intervention group
Group type: COMPARATOR
Intervention: No oral stimulation
Number of subjects: 16
Study 9862944 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone (1500 mg daily)
Number of subjects: 1057
Study 9862944 — intervention group
Group type: COMPARATOR
Intervention: Dapsone (100 mg daily)
Number of subjects: 1057
Study 9862944 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone
Number of subjects: 1057
Study 9862944 — intervention group
Group type: COMPARATOR
Intervention: Dapsone
Number of subjects: 1057
Study 8077767 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese hamster glycosylated recombinant interferon‐beta (rHuIFN‐beta)
Number of subjects: 12
Study 8077767 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural IFN‐beta (Frone)
Number of subjects: 12
Study 2792395 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecatwin/Feca EIA (combined guaiac and immunological test)
Number of subjects: 535
Study 1098594 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinestrol 2 mg
Number of subjects: 196
Study 1098594 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinestrol 4 mg
Number of subjects: 196
Study 1098594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 31610998 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated motivational interviewing and exercise intervention (12-week multi-modal exercise program)
Number of subjects: 68
Study 31610998 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated motivational interviewing and exercise intervention
Number of subjects: 68
Study 31610998 — intervention group
Group type: COMPARATOR
Intervention: Control/delayed condition
Number of subjects: 68
Study 28624483 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF (LVEF ≥50%)
Number of subjects: 843
Study 28624483 — intervention group
Group type: EXPERIMENTAL
Intervention: HFmrEF (LVEF 40% to 49%)
Number of subjects: 843
Study 28624483 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF (LVEF <40%)
Number of subjects: 843
Study 25989827 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced glutathione 1800 mg (n=416)
Number of subjects: 825
Study 25989827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=411)
Number of subjects: 825
Study 23799707 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension control program
Number of subjects: 4902
Study 21723606 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 0.5 mg
Number of subjects: 72
Study 21723606 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg
Number of subjects: 72
Study 21723606 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 10 mg
Number of subjects: 72
Study 21723606 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 0.5 mg, 2.5 mg, 10 mg
Number of subjects: 72
Study 21723606 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 72
Study 21723606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20070724 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 69
Study 20070724 — intervention group
Group type: COMPARATOR
Intervention: Oral dydrogesterone
Number of subjects: 69
Study 16490616 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d plus ezetimibe 10 mg/d
Number of subjects: 203
Study 16490616 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg/d
Number of subjects: 203
Study 15072629 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 120
Study 15072629 — intervention group
Group type: COMPARATOR
Intervention: Open Prostatectomy
Number of subjects: 120
Study 15072629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HoLEP and Open Prostatectomy
Number of subjects: 120
Study 10885234 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg.kg‐1 intravenous bolus injection followed by 6 mg.kg‐1.h‐1 infusion)
Number of subjects: 28
Study 10885234 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (1 mg.kg‐1 intravenous bolus injection followed by 1 mg.kg‐1.h‐1 infusion)
Number of subjects: 28
Study 10885234 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (5 micrograms.kg‐1 injection)
Number of subjects: 28
Study 8836022 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling of patients with STD, combined with contact slip(s)
Number of subjects: 396
Study 8836022 — intervention group
Group type: COMPARATOR
Intervention: Control group (no individual counseling)
Number of subjects: 396
Study 8836022 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling of women with STD
Number of subjects: 396
Study 1345803 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 69
Study 1345803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 1345803 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF and Placebo
Number of subjects: 69
Study 6441958 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin treatment
Number of subjects: 21
Study 6441958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30985218 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (n = 38)
Number of subjects: 55
Study 30985218 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotic (n = 17)
Number of subjects: 55
Study 30120403 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Formula (EF) supplemented with bovine milk fat globule membranes
Number of subjects: 160
Study 30120403 — intervention group
Group type: COMPARATOR
Intervention: Standard Formula
Number of subjects: 160
Study 25794220 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength training of the neck flexors
Number of subjects: 145
Study 24083783 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention focused on general practitioners (GPs) including training, electronic blood pressure measurement device, and recommendation leaflet
Number of subjects: 1832
Study 24083783 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention focused on general practitioners (GPs)
Number of subjects: 1832
Study 24083783 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1832
Study 21906708 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographically plus computed tomographically guided (ACTG)
Number of subjects: 71
Study 21906708 — intervention group
Group type: COMPARATOR
Intervention: Angiographically guided
Number of subjects: 71
Study 18653315 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot juice (330 mL daily)
Number of subjects: 0
Study 18653315 — intervention group
Group type: COMPARATOR
Intervention: Tomato juice (330 mL daily)
Number of subjects: 0
Study 18653315 — intervention group
Group type: COMPARATOR
Intervention: Spinach powder (10 g daily)
Number of subjects: 0
Study 18653315 — intervention group
Group type: COMPARATOR
Intervention: Low carotenoid period
Number of subjects: 0
Study 16780548 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis (valganciclovir 900 mg q.d. for 100 days)
Number of subjects: 98
Study 16780548 — intervention group
Group type: COMPARATOR
Intervention: Preemptive therapy (valganciclovir 900 mg b.i.d. for 21 days)
Number of subjects: 98
Study 14606102 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RAB) 10 mg
Number of subjects: 40
Study 10960446 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 42
Study 10960446 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 8877029 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg)
Number of subjects: 6
Study 8877029 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (2 mg)
Number of subjects: 6
Study 8877029 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (6 mg)
Number of subjects: 6
Study 8877029 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide plus naloxone
Number of subjects: 6
Study 8877029 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone alone
Number of subjects: 6
Study 8877029 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 6
Study 8877029 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 6
Study 1889499 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiophene carboxylate (600 mg per day for 21 days)
Number of subjects: 33
Study 1889499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 6529891 — intervention group
Group type: EXPERIMENTAL
Intervention: Self blood glucose monitoring by meter
Number of subjects: 24
Study 6529891 — intervention group
Group type: EXPERIMENTAL
Intervention: Self blood glucose monitoring by visually read strips
Number of subjects: 24
Study 6529891 — intervention group
Group type: COMPARATOR
Intervention: Urine glucose monitoring
Number of subjects: 24
Study 3886851 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (Group 1, 62 cases)
Number of subjects: 174
Study 3886851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 2, 60 cases)
Number of subjects: 174
Study 3886851 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (Group 3, 25 cases)
Number of subjects: 174